Literature DB >> 25588330

Does metabolic syndrome increase the risk of infective complications after prostate biopsy? A critical evaluation.

Cahit Sahin1, Bilal Eryildirim, A Cihangir Cetinel, Gokhan Faydaci, Fehmi Narter, Cemal Goktas, Kemal Sarica.   

Abstract

PURPOSE: To evaluate the possible association between metabolic syndrome (MetS) and infectious complications after prostate biopsy.
METHODS: A total of 480 men underwent prostatic biopsy due to elevated prostate-specific antigen levels and/or abnormal digital rectal examination. Patients were divided into two subgroups with respect to the presence or absence of MetS. Patients in both groups were closely followed with respect to infectious complications after biopsy and the possible effect of MetS as a certain risk factor on these complications was evaluated with a multivariate analysis.
RESULTS: Infectious complications were observed in 33 cases (6.8%), while urinary tract infection (UTI) was detected in 30 (6.2%) cases, sepsis occurred in three (0.6%) cases. The percentage of the cases with infectious complications was 11.0 and 3.4% in men with and without MetS, respectively (p = 0.002). These rates were 3.7 versus 1.5%, respectively, for UTI (p < 0.003) and 0.9 versus 0.4%, respectively, for sepsis in both groups (p = 0.594). Multivariate analysis of the data confirmed that MetS was associated with an increased risk of infective complications (odds ratio 3.44 and 95% CI 1.56-7.58, p < 0.002) after this procedure.
CONCLUSIONS: MetS could pose a certain increased risk for infectious complications after prostate biopsy. Patients with MetS should be considered as risk cases for this procedure, and they should be evaluated and followed in a very close manner with respect to these complications.

Entities:  

Mesh:

Year:  2015        PMID: 25588330     DOI: 10.1007/s11255-014-0904-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

Review 1.  Overactive bladder: Is there a link to the metabolic syndrome in men?

Authors:  Michael G Kirby; Adrian Wagg; Linda Cardozo; Christopher Chapple; David Castro-Diaz; Dirk de Ridder; Montserrat Espuna-Pons; Francois Haab; Con Kelleher; Heinz Kölbl; Ian Milsom; Philip Van Kerrebroeck; Mark Vierhout; Stefano Salvatore; Andrea Tubaro
Journal:  Neurourol Urodyn       Date:  2010-11       Impact factor: 2.696

2.  Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases.

Authors:  G Igor Pinkhasov; Yu-Kuan Lin; Ricardo Palmerola; Paul Smith; Frank Mahon; Matthew G Kaag; J Edward Dagen; Lewis E Harpster; Carl T Reese; Jay D Raman
Journal:  BJU Int       Date:  2012-02-07       Impact factor: 5.588

3.  Niacin and HDL cholesterol--time to face facts.

Authors:  Donald M Lloyd-Jones
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

4.  Do atherosclerosis and chronic bladder ischemia really play a role in detrusor dysfunction of old age?

Authors:  Ofer Z Shenfeld; Karen S Meir; Vladimir Yutkin; Ofer N Gofrit; Ezekiel H Landau; Dov Pode
Journal:  Urology       Date:  2005-01       Impact factor: 2.649

5.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

6.  Is it possible to predict sepsis, the most serious complication in prostate biopsy?

Authors:  Adnan Simsir; Erkan Kismali; Rashad Mammadov; Gurhan Gunaydin; Cag Cal
Journal:  Urol Int       Date:  2010-03-12       Impact factor: 2.089

7.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

8.  Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor.

Authors:  Ashraf A Mosharafa; Mohamed H Torky; Wael M El Said; Alaa Meshref
Journal:  Urology       Date:  2011-07-22       Impact factor: 2.649

Review 9.  Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.

Authors:  A Ponholzer; S Madersbacher
Journal:  Int J Impot Res       Date:  2007-07-05       Impact factor: 2.896

Review 10.  Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies.

Authors:  Ken T Coppieters; Matthias G von Herrath
Journal:  Mol Metab       Date:  2014-01-21       Impact factor: 7.422

View more
  2 in total

1.  Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy.

Authors:  Xue-Fei Ding; Yang Luan; Sheng-Ming Lu; Guang-Chen Zhou; Tian-Bao Huang; Liang-Yong Zhu; Cheng-Hao Guo
Journal:  World J Urol       Date:  2020-09-19       Impact factor: 4.226

2.  Number of Metabolic Syndrome Components Is the Central Predictor of the Impact of Metabolic Syndrome on Outcome of Percutaneous Nephrolithotomy in Staghorn Nephrolithiasis.

Authors:  Peng Xu; Jia Wang
Journal:  J Endourol       Date:  2019-09-20       Impact factor: 2.942

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.